Piramal Pharma (PPLPHARMA) Q4 20/21 earnings summary

Executive summary

• First reporting period ran from March 4, 2020 to March 31, 2021; consolidated net sales were ₹6,314.90 crore and net profit after tax, including associates and joint ventures, was ₹835.03 crore.

• Standalone revenue from operations was ₹2,938.81 crore and net profit was ₹571.50 crore for the same period.

Financial highlights

• Consolidated OPBIDTA was ₹1,592.07 crore, profit before tax and exceptional items ₹883.58 crore, and net profit before associate/JV profit ₹787.79 crore.

• Standalone total income was ₹3,136.78 crore; profit before exceptional items and tax was ₹668.55 crore and profit after tax ₹571.50 crore.

• Standalone exceptional items netted to income of ₹18.23 crore: ₹100.85 crore forward-contract mark-to-market gain, offset by asset write-offs of ₹37.43 crore and transaction costs of ₹45.19 crore.

Outlook and guidance

• The planned Hemmo Pharmaceuticals acquisition remained subject to customary closing conditions and regulatory approvals; agreed terms included ₹775 crore upfront plus milestone-linked earn-outs.

• Economic and pandemic effects remained uncertain; management planned to continue monitoring future conditions and considered available resources adequate for continued operations.